"Specialty drugs" is a term that has entered common vocabulary to categorize a class of drugs that are clinically unrelated, but are increasingly grouped together due to their high cost. They have come under scrutiny lately from payers, policymakers, and physicians and exemplify the most significant, recurring challenge in modern health care: how to balance effective innovation with fiscally viable pricing. Unfortunately, solutions are elusive because of pervasive myths about these products, often perpetuated due to conflicting motives of buyers or sellers. Below we debunk the most serious myths impeding an effective policy response.
Read Full Article »
